Key Highlights

  • Cryoport (NASDAQ:CYRX) was trading up 20.22% at USD 19.30 on Friday, November 6, 2026, the day after it released third-quarter 2026 results following the close on November 5.
  • Third-quarter Revenue rose 14% to USD 50.2 million from USD 44.2 million, with commercial cell and gene therapy revenue up 20% from a year earlier.
  • Full-year 2026 revenue guidance was raised to USD 197 million to USD 199 million, and adjusted EBITDA from continuing operations turned positive at USD 1.1 million.
  • Cash, equivalents and short-term investments were USD 393.1 million, while the net loss widened to USD 10.9 million from USD 6.9 million.

Third-Quarter Revenue Growth and a Higher Full-Year Range

Cryoport (NASDAQ:CYRX) reported third-quarter 2026 results on November 5, 2026, after the market close, and the shares were trading up 20.22% at USD 19.30 on the screener the next day. Revenue was USD 50.2 million, up 14% from USD 44.2 million. Life Sciences Services grew 18% to USD 28.6 million, and Life Sciences Products grew 8% to USD 21.7 million. Management raised 2026 revenue guidance to USD 197 million to USD 199 million. A raised range is the usual reason investors reprice a growth stock, because it lifts the base for next year's comparisons. The 14% growth rate also sits alongside 20% growth in commercial therapy revenue, which management credited for core Business momentum.

What Cryoport Does and Where Momentum Came From

Cryoport provides temperature-controlled logistics, storage and related services for cell and gene therapies, where products must stay frozen in transit. It supports 23 commercial therapies and a record 788 clinical trials, according to the release. BioLogistics Solutions grew 16% to USD 22.5 million, and BioStorage and BioServices grew 25% to USD 6.0 million. Commercial cell and gene therapy revenue grew 20%, which shows Demand tied to approved treatments rather than only trial activity. Adjusted EBITDA from continuing operations was USD 1.1 million, against a loss of USD 0.6 million, a milestone the company framed within its pathway to profitability initiative. Management said the results give it confidence in its outlook.

Wider Net Loss, Balance Sheet and the Risks Ahead

Profit measures were mixed. The net loss was USD 10.9 million against USD 6.9 million, and the net loss attributable to common stockholders was USD 12.9 million, or USD 0.25 per share. Cash, equivalents and short-term investments were USD 393.1 million, a large cushion against that loss. Risks include dependence on a small group of approved therapies and clinical programs, product mix changes and the pace of the profitability plan. A 20.22% single-day gain also raises the bar for the next report, and moves of this size can retrace. Investors can watch whether the guidance range holds and whether EBITDA stays positive and whether the net loss narrows from USD 10.9 million as scale builds in the services business.

Where Things Stand

The move appears to be a reaction to results. Cryoport (NASDAQ:CYRX) was up 20.22% at USD 19.30 after it reported 14% revenue growth, a higher full-year range and positive adjusted EBITDA, while the wider net loss is the counterweight. The release came after the November 5, 2026 close, which fits the timing of the gain, although the reaction itself is read from the screener rather than from a company statement. The next markers are fourth-quarter delivery against the raised guidance and whether adjusted EBITDA stays positive and how quickly the USD 393.1 million cash cushion is matched by reported profit rather than a wider loss.